WeVote
Log In

Bill

Bill

HB 4392

Banning certain dyes from pharmaceutical products

2026 Regular Session Introduced by Adam Burkhammer

West Virginia proposes banning specified dyes in pharmaceuticals, potentially affecting drug formulations, manufacturer compliance, and medication availability in the state.

Markup Discussion
#health
0
WeVote Research Nonpartisan
Bill Summary · HB 4392

Legislative bill overview

HB 4392 proposes to prohibit certain dyes from being used in pharmaceutical products manufactured or distributed in West Virginia. The bill has been introduced in the West Virginia House of Representatives and is currently under committee review in the House Health and Human Resources Committee.

Why is this important

Pharmaceutical dyes serve functional purposes like identifying medications and improving patient compliance, but some dyes have been subject to safety scrutiny. This legislation could affect drug manufacturers' formulation options, potentially impact drug availability in West Virginia, and may influence broader pharmaceutical manufacturing practices if other states follow suit.

Potential points of contention

  • Specificity of banned dyes: The bill's language on which specific dyes are prohibited remains unclear from available information; overly broad restrictions could limit medication options while narrow ones may not address safety concerns effectively.
  • Federal-state regulatory conflict: The FDA already regulates pharmaceutical dyes at the federal level; state-level bans could create compliance complications for manufacturers and potentially conflict with existing federal approvals.
  • Economic and supply chain impact: Manufacturers may reformulate products, increase costs, or limit availability in West Virginia, potentially creating drug shortages or price increases for consumers and healthcare providers.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.